In many parts of the world, IgA nephropathy is the most common form of glomerulonephritis--a disease that damages the tiny filtering units of the kidney, called glomeruli. IgA nephropathy (nuh-FROP-uh-thee), also known as Berger's disease, is a kidney disease that occurs when an antibody called immunoglobulin A (IgA) lodges in your kidneys. IgA nephropathy usually progresses slowly over many years, but the course of the disease in each person is uncertain. Primary IgA nephropathy is characterized by deposition of the IgA antibody in the glomerulus. In IgA nephropathy there is a slow progression to chronic kidney failure in 25-30% of cases during a period of 20 years.
Using corticosteroids (CS) to treat patients with IgA nephropathy decreases the risk of disease progression regardless of initial estimated glomerular filtration rate (eGFR), new research suggests.
Current guidelines suggest CS treatment in patients with IgA nephropathy (IgAN) when eGFR is higher than 50 mL/min/1.73 m2 and proteinuria is persistently 1 g/day or more despite 3–6 months of supportive care. Whether the benefits of this treatment extend to patients with an eGFR of 50 mL/min/1.73 m2 or below, other levels of proteinuria, or different renal pathologic lesions remains unknown, according to researchers.
In a retrospective study, Rosanna Coppo, MD, of Turin Hospital in Turin, Italy, and colleagues analyzed data from 1,147 patients with IgAN from the European Validation Study of the Oxford Classification of IgAN (VALIGA) cohort. Physicians prescribed immunosuppression for 46% of the patients. Of these, 98% received CS.
Using a propensity score, the investigators matched 184 patients who received CS and renin-angiotensin system blockade (RASB) to 184 patients with a similar risk profile of progression who received only RASB. At the time of biopsy, 115 of the 368 patients had an eGFR of 50 mL/min/1.73 m2 or less (54 who received RASB alone and 61 who received CS and RASB) and 253 had an eGFR above 50 mL/min/1.73 m2 (130 who received RASB alone and 123 who received CS and RASB).
In the propensity score-matched subgroup, CS treatment decreased proteinuria and the rate of renal function decline and increased renal survival, Dr. Coppo's group reported online ahead of print in the Journal of the American Society of Nephrology. During the entire follow-up, mean proteinuria values declined by 0.8 g/day in the CS-RASB group compared with a decline of 3.2 g/day in the RASB group. Renal function declined by 1.0 mL/min/1.73 m2 per year in the CS-RASB group versus a decline of 3.2 mL/min/1.73 m2 per year in the RASB group.
A total of 84 patients in the CS group experienced a reduction in proteinuria to less than 1 g/day compared with 54 patients in the RASB group. A reduction in proteinuria to ESRD developed in 7 patients in the CS-RASB group compared with 20 in the RASB group. All of these between-group differences were statistically significant.
These benefits extended to patients with an eGFR of 50 mL/min/1.73 m2 or less, with the benefits increasing proportionately with the level of proteinuria. Among the patients in this subgroup, eGFR declined by 0.3 mL/min/1.73 m2 per year in the CS-RASB recipients compared with a decline of 4.8 mL/min/1.73 m2 per year in the RASB group. In addition, 74% in the CS group reached a proteinuria level below 1 g/day compared with 37% of the RASB group.
“Although this retrospective analysis cannot provide an explicit recommendation for the use of CS within this group until randomized trials confirm our findings, clinicians should consider this option, especially in those with an elevated proteinuria despite optimal conservative therapy,” the authors concluded.
To sum up, you can know about corticosteroids okay for igA nephropathy regardless of renal function. If you want to know more information, you can send email to kidneyhospitalabroad@hotmail.com. You can contact us online doctors.
Using corticosteroids (CS) to treat patients with IgA nephropathy decreases the risk of disease progression regardless of initial estimated glomerular filtration rate (eGFR), new research suggests.
Current guidelines suggest CS treatment in patients with IgA nephropathy (IgAN) when eGFR is higher than 50 mL/min/1.73 m2 and proteinuria is persistently 1 g/day or more despite 3–6 months of supportive care. Whether the benefits of this treatment extend to patients with an eGFR of 50 mL/min/1.73 m2 or below, other levels of proteinuria, or different renal pathologic lesions remains unknown, according to researchers.
In a retrospective study, Rosanna Coppo, MD, of Turin Hospital in Turin, Italy, and colleagues analyzed data from 1,147 patients with IgAN from the European Validation Study of the Oxford Classification of IgAN (VALIGA) cohort. Physicians prescribed immunosuppression for 46% of the patients. Of these, 98% received CS.
Using a propensity score, the investigators matched 184 patients who received CS and renin-angiotensin system blockade (RASB) to 184 patients with a similar risk profile of progression who received only RASB. At the time of biopsy, 115 of the 368 patients had an eGFR of 50 mL/min/1.73 m2 or less (54 who received RASB alone and 61 who received CS and RASB) and 253 had an eGFR above 50 mL/min/1.73 m2 (130 who received RASB alone and 123 who received CS and RASB).
In the propensity score-matched subgroup, CS treatment decreased proteinuria and the rate of renal function decline and increased renal survival, Dr. Coppo's group reported online ahead of print in the Journal of the American Society of Nephrology. During the entire follow-up, mean proteinuria values declined by 0.8 g/day in the CS-RASB group compared with a decline of 3.2 g/day in the RASB group. Renal function declined by 1.0 mL/min/1.73 m2 per year in the CS-RASB group versus a decline of 3.2 mL/min/1.73 m2 per year in the RASB group.
A total of 84 patients in the CS group experienced a reduction in proteinuria to less than 1 g/day compared with 54 patients in the RASB group. A reduction in proteinuria to ESRD developed in 7 patients in the CS-RASB group compared with 20 in the RASB group. All of these between-group differences were statistically significant.
These benefits extended to patients with an eGFR of 50 mL/min/1.73 m2 or less, with the benefits increasing proportionately with the level of proteinuria. Among the patients in this subgroup, eGFR declined by 0.3 mL/min/1.73 m2 per year in the CS-RASB recipients compared with a decline of 4.8 mL/min/1.73 m2 per year in the RASB group. In addition, 74% in the CS group reached a proteinuria level below 1 g/day compared with 37% of the RASB group.
“Although this retrospective analysis cannot provide an explicit recommendation for the use of CS within this group until randomized trials confirm our findings, clinicians should consider this option, especially in those with an elevated proteinuria despite optimal conservative therapy,” the authors concluded.
To sum up, you can know about corticosteroids okay for igA nephropathy regardless of renal function. If you want to know more information, you can send email to kidneyhospitalabroad@hotmail.com. You can contact us online doctors.
Doc, Chukwu Madu herbal home. You are so great sir, I am cured from HIV/AIDS Virus through the help of your mighty herbs. It happened as you said, you never let me down sir I was tested HIV/aids Negative 5 days ago right here in my Country same hospital that tested me positive some months ago. I didn't accept at the first time you saved me from death Sir DR CHUKWU MADU HERBAL HOME, with your herbs.Thank you so much sir. If you are going through any of this virus or infection reach this great herbalist on his personal email:[ dr.chukwumaduherbalhome@gmail.com ] or WhatsApp him via +2347030936239. He will save you.
ReplyDeleteThanks: my name 'DUNURAI WAYAN' From CHINA